A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1). * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. * Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode. Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Study sites (24)
CA
- Neurocrine Clinical Site · Oceanside, CA 92056More trials in Oceanside
- Neurocrine Clinical Site · Orange, CA 92868More trials in Orange
- Neurocrine Clinical Site · San Jose, CA 95124More trials in San Jose
CT
- Neurocrine Clinical Site · New Haven, CT 06520More trials in New Haven
FL
- Neurocrine Clinical Site · Miami Gardens, FL 33014More trials in Miami Gardens
- Neurocrine Clinical Site · Orlando, FL 32803More trials in Orlando
- Neurocrine Clinical Site · Palm Bay, FL 32905More trials in Palm Bay
- Neurocrine Clinical Site · Tampa, FL 33629More trials in Tampa
IA
- Neurocrine Clinical Site · Iowa City, IA 52242More trials in Iowa City
LA
- Neurocrine Clinical Site · Marrero, LA 70072More trials in Marrero
MO
- Neurocrine Clinical Site · O'Fallon, MO 63368More trials in O'Fallon
NC
- Neurocrine Clinical Site · Charlotte, NC 28211More trials in Charlotte
NM
- Neurocrine Clinical Site · Albuquerque, NM 87109More trials in Albuquerque
NY
- Neurocrine Clinical Site · Glen Oaks, NY 11004More trials in Glen Oaks
OK
- Neurocrine Clinical Site · Edmond, OK 73013More trials in Edmond
- Neurocrine Clinical Site · Oklahoma City, OK 73112More trials in Oklahoma City
PA
- Neurocrine Clinical Site · Philadelphia, PA 19104More trials in Philadelphia
TX
- Neurocrine Clinical Site · Austin, TX 78712More trials in Austin
- Neurocrine Clinical Site · Bellaire, TX 77401More trials in Bellaire
- Neurocrine Clinical Site · Friendswood, TX 77546More trials in Friendswood
- Neurocrine Clinical Site · Stafford, TX 77477More trials in Stafford
- Neurocrine Clinical Site · Wichita Falls, TX 76309More trials in Wichita Falls
UT
- Neurocrine Clinical Site · Draper, UT 84020More trials in Draper
VA
- Neurocrine Clinical Site · Roanoke, VA 24018More trials in Roanoke